IBIO vs RXRX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IBIO and RXRX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IBIO and RXRX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

iBio, Inc. is a clinical-stage biotechnology company that applies artificial intelligence and proprietary 3D modeling of subdominant and conformational epitopes to discover antibodies that other approaches have struggled to develop. Its focus is obesity, cardiometabolic, and cardiopulmonary diseases, an area drawing intense interest as GLP-1 weight-loss drugs create demand for therapies that preserve lean muscle mass. The lead program, IBIO-600, is a long-acting anti-myostatin antibody engineered for infrequent dosing that iBio positions as potentially best-in-class; the company dosed the first participant in a Phase 1 trial in Australia in 2026, becoming a clinical-stage company. A second program, IBIO-610, is an activin E antibody that reduced visceral and total fat in obese non-human primate studies.

Full IBIO guide

Recursion Pharmaceuticals is a Salt Lake City-based, clinical-stage technology-enabled biopharmaceutical company that aims to industrialize drug discovery. Its platform combines automated wet-lab biology, high-throughput cellular imaging that generates petabytes of proprietary experimental data, and machine-learning models that map relationships between genes, compounds, and disease, layered with Exscientia's automated precision molecular design. Recursion intends to make money three ways: partnership and collaboration payments (upfront fees, research funding, and milestone payments from large pharma companies that use its platform), future royalties on any partnered drugs that reach market, and value from its own wholly owned pipeline of clinical candidates. Today the company is pre-revenue in the product sense: reported revenue is small (roughly $6.5 million in Q1 2026) and comes mostly from partnerships rather than drug sales.

Full RXRX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• IBIO drivers: AI antibody-discovery platform; Obesity and muscle-preservation wave.
• RXRX drivers: An industrial-scale AI platform and proprietary data moat; A deep big-pharma partnership book.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is that iBio is a speculative, essentially pre-revenue micro-cap whose survival depends on continually raising money. For RXRX, the central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $117.5 million in Q1 2026 against only about $6.5 million of revenue, so the entire valuation rests on platform promise rather than proven output.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick IBIO if you believe its drivers more; RXRX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IBIO and RXRX guides.

IBIO. Figures are approximate and tied to the asOf date; verify live numbers before acting. For a pre-revenue clinical-stage biotech, traditional valuation multiples such as P/E are not meaningful because there are no sustained earnings. What matters far more is cash runway versus burn rate, the pace and results of clinical trials, and how much dilution future funding requires. Treat any single quarter's cash figure and any analyst target as a snapshot, not a stable anchor.

RXRX. Because Recursion is pre-profit with minimal revenue, traditional earnings multiples do not apply, and the figures that matter most are cash on hand, the rate of cash burn, and how long the runway lasts before the company must raise money again. Q1 2026 showed narrower losses driven by sizable cuts to R&D and overhead, which extended the stated runway into early 2028, but revenue came in well below analyst expectations. For a story like this, valuation is ultimately a bet on future platform output and partnership milestones rather than on current financial performance.

Headline figures (approximate, Jul 2026): IBIO shows revenue Essentially none from products; iBio is a clinical-stage biotech with only minimal reported revenue, so standard sales-based metrics do not apply, net loss Consistently loss-making, as expected for a company investing in R&D ahead of any approved product; losses are funded by capital raises, cash position / runway Roughly $74.8 million in cash, equivalents, and debt securities as of March 31, 2026; management has said financings extend the runway into fiscal 2028, market cap (micro-cap) In the tens of millions of dollars in mid-2026, placing IBIO firmly in micro-cap territory with the volatility that implies; RXRX shows revenue (q1 2026) ~$6.5 million (mostly partnership and milestone revenue, missed analyst estimates), net loss (q1 2026) ~$117.5 million (narrowed from the prior year on cost cuts), cash and investments ~$665 million (as of March 31, 2026), guided 2026 operating cash burn less than ~$390 million; stated runway into early 2028 without new financing.

IBIO and RXRX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IBIO and RXRX exposure against your real portfolio. It is not an investment adviser.